Thanks to modern treatments, HIV, though incurable, is far from the death sentence it once was. But it is still a life sentence, coming with the high cost, both personal and economic, of chronic disease, making avoiding infection in the first place a major goal for public health agencies. To that end, after numerous trials, the FDA has now approved Truvada, a combination drug that is already being used to treat HIV, as a preventative.
Last April, we reported on the failure of Truvada, an oral anti-HIV pill, to prevent infection in African women. The results of the trial were disappointing, and surprising, because Truvada had been found to prevent infection in 90% of gay men who took it religiously. We pointed out at the time that the researchers had yet to analyze blood samples they’d taken from the women in the study. Those samples would show whether the women had been taking the drug as prescribed, which would suggest that its failure was due to some biological factor, or whether they had been failing to take the drug.
It looks like it’s the latter. This week, the NYTimes reports, the researchers announced at an AIDS research conference in Seattle that of the women who got infected, only a quarter of them had any Truvada at all in their blood. Read More